The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival.
 
Elizabeth Rodriguez
No Relationships to Disclose
 
Tori Tonn
Consulting or Advisory Role - Becton Dickinson (I)
 
Midhat Jafry
No Relationships to Disclose
 
Qian Xiao
No Relationships to Disclose
 
Branko Cuglievan
No Relationships to Disclose
 
Sairah Ahmed
Honoraria - ADC Therapeutics
Consulting or Advisory Role - Myeloid Therapeutics; Sanofi; Tessa Therapeutics
Research Funding - Chimagen Biosciences (Inst); Merck (Inst); Seagen (Inst); Tessa Therapeutics (Inst); Xencor (Inst)
 
J Andrew Andrew Livingston
Consulting or Advisory Role - Foghorn Therapeutics
Research Funding - Repare Therapeutics (Inst)
Other Relationship - Guidepoint Global
 
Gregory John Aune
Consulting or Advisory Role - LumaBridge
 
Karen H. Albritton
No Relationships to Disclose
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Pharmacyclics/Janssen; SeaGen; Spectrum Pharmaceuticals
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Michael Roth
Research Funding - Eisai; Pfizer
 
Michelle Ann Theobald Hildebrandt
No Relationships to Disclose